IL1RAP and chronic myelogenous leukemia, BCR-ABL1 positive: Targeting IL1RAP with anti-IL1RAP antibodies kills CML cells and improves the survival of mouse xenografts by inhibiting IL-1B signaling and inducing antibody-dependent cytotoxicity [77].